INTRODUCTION {#sec0005}
============

Alzheimer's disease (AD) is a neurodegenerative disorder manifesting as progressive cortical and hippocampal cell loss resulting in cognitive decline. It is the leading form of dementia in the elderly being both sporadic and familial in nature, and to date there is no effective therapy to arrest the cognitive decline. The two major hallmarks of AD pathology are the accumulations of the ∼4 kD amyloid-β peptide (Aβ), the cleavage product of the larger amyloid-β protein precursor (AβPP), and the accumulation of intracellular neurofibrillary tangles which consist of hyperphosphorylated microtubule associated protein tau. Recently, a study in the APP/PS1 (APP KM670/671NL (Swedish), PSEN1 L166P) transgenic mouse model of AD that contains the human transgenes for both APP bearing the Swedish mutation and Presenillin1 containing the L166P mutation, indicated that the stable disaccharide, trehalose dihydrate, effectively alleviated cognitive decline as evidenced by a reduced latency to locate the hidden platform in the Morris water maze, concomitant with reduced Aβ plaques in the hippocampus of the trehalose treated mice \[[@ref001]\]. While these data were encouraging, the utility of trehalose as a potential therapeutic for AD was clouded by the delivery method, which involved the use of invasive intracerebral injections. Given these data, we elected to examine the therapeutic utility of trehalose in the well characterized and widely used Tg2576 (APP KM670/671L) transgenic mouse model of AD using a more physiologically relevant and translatable oral delivery method. The Tg2576 overexpresses a mutant form of APP (695 isoform) resulting in elevated levels of Aβ and an age-associated accumulation of amyloid plaques concomitant with cognitive deficits.

Trehalose has demonstrated therapeutic utility in many other neurodegenerative mouse models. Briefly, trehalose has been shown to suppress inflammation, oxidative stress, and vasospasm induced by experimental subarachnoid hemorrhage in rabbits \[[@ref002]\], induce chaperone molecules along with autophagy in a mouse model of Lewy body disease \[[@ref003]\], ameliorate dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation \[[@ref004]\], delay the progression of amyotrophic lateral sclerosis by enhancing autophagy in motorneurons \[[@ref005]\], alleviate polyglutamine-mediated pathology in a mouse model of Huntington disease \[[@ref006]\], and upregulate progranulin expression in human and mouse models of progranulin haploinsufficiency \[[@ref007]\]. Given the breadth of positive data regarding trehalose in animal models of neurodegeneration, the potential for the use of trehalose as a human therapeutic for AD has been hypothesized \[[@ref008]\], although this yet to be thoroughly investigated.

Finally, the metal ions, iron (Fe) \[[@ref010]\], zinc (Zn) \[[@ref013]\], and copper (Cu) \[[@ref015]\], are considered key factors in the pathogenic accumulation of Aβ into amyloid plaques as well as to the loss of tau function and neurofibrillary tangle formation. This concept arose more than two decades ago and has been the subject of much scientific review \[[@ref018]\], prompting discussion around the potential of metal modulating therapies \[[@ref022]\], leading to investigation of the therapeutic efficacy of metal modulating compounds in transgenic animal models of AD \[[@ref027]\] and in human clinical trials \[[@ref031]\]. As such, and because the effect of trehalose in other models suggests a potential impact on metals (e.g., effects on protein aggregation, oxidative stress, cognition, etc.), then in this study we also sought to determine whether trehalose treatment impacted metal levels, or indeed whether there was any correlation between metal levels and outcomes following trehalose treatment.

METHODS {#sec0010}
=======

All procedures were carried out in accordance with protocols approved by the Howard Florey Animal Ethics Committee and were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes as described by the National Health and Medical Research Council of Australia.

Compound {#sec0015}
--------

Trehalose (Sigma) has a generous safety profile in rodents and humans \[[@ref032]\] and was posted as "Generally Regarded as Safe" (GRAS) for human consumption by the U.S. Federal Drug Administration (FDA) in October 2000. It is used as a food additive, and is also an excipient in many pharmaceuticals, making trehalose a safe, natural and pharmaceutically accepted product.

Animals {#sec0020}
-------

Transgenic Tg2576 and wild-type mice were treated daily with either a 2% trehalose solution (0.1 ml/10 g bodyweight; Tg2576; *n* = 15, average age 16.2±3 months of age, and wild-type; *n* = 10, average age 16.4±3 months of age) or standard suspension vehicle (SSV; 0.9% NaCl, 0.5% Na-carboxymethylcellulose, 0.5% benzyl alcohol and 0.4% Tween 80) (Tg2576; *n* = 12, 16±3 months of age, and wildtype; *n* = 10, 16.2±3 months of age) via oral gavage. Mice were acquired from Charles River Laboratories, Wilmington, Massachusetts, USA. All mice used in this study were re-genotyped after completion of the study to ensure accuracy of transgenic background.

Behavioral assessment {#sec0025}
---------------------

The Morris water maze was used to assess the effect of trehalose on spatial learning and memory function. The pre-training acclimation day of the water maze was performed on day 23 of dosing, followed by six days of place discrimination training of four 90 second trials per day, conducted on days 24--29 of dosing. The probe trial was performed 24 hours after training on dosing day 30 to assess retention of the task. Mice were culled on the following day one hour after dosing. Data was processed using the Ethovision automated tracking system prior to statistical analysis.

Western blotting analysis {#sec0030}
-------------------------

The cortex and hippocampus of one hemisphere was homogenized in 15 volumes of ice-cold PBS containing Complete Protease Inhibitor Cocktail tablets (Roche Applied Science, Indianapolis, IN, USA) and subsequently centrifuged (100,000xg) for 30 min at 4°C. Supernatant was removed to yield the soluble fraction. The remaining pellet underwent further extraction via vigorous agitation (30 min) in the above-mentioned homogenization buffer containing 2% (vol/vol) Triton X100. Insoluble material was pelleted via centrifugation (20,000 g, 20 min), and the supernatant retained as the membrane fraction. Protein concentrations were determined using the Pierce BCA protein assay (Pierce Biotechnology, Rockford, IL, USA), and were used to ensure equal protein loading (10 μg) on the gel. Samples were prepared for PAGE by the addition of 4x protein sample loading buffer (LICOR, Lincoln, Nebraska, USA) and 10x NuPAGE sample reducing agent (to a final 1x concentration). Samples were heated to 70°C for 10 min, loaded onto Bolt 4--12% Bis-Tris Plus gels (Invitrogen-Life Technologies, Grand Island, NY, USA) along with Odyssey One-Color protein molecular weight markers (LICOR, Lincoln, Nebraska, USA, Cat LCR928-4000) and run at 125 V for 60 min in appropriately diluted Bolt MES SDS 20x running buffer (Invitrogen-Life Technologies, Grand Island, NY, USA). Gels were transferred to Immobilon--PF, PVDF membrane (Millipore) using the Invitrogen Bolt wet-gel Transfer Device (Invitrogen-Life Technologies, Grand Island, NY, USA) at 15 V for 60 min in appropriately diluted 20x Bolt transfer buffer (Invitrogen-Life Technologies, Grand Island, NY, USA). Membranes were blocked in Tris-buffered saline with tween 20 (TBST) containing 5% skim milk powder and then incubated with primary antibody overnight at 4°C (Doublecortin (DCX) antibody diluted 1 : 1000, Cell Signaling Technology, Danvers, MA, USA Cat \# 4604; Synaptophysin antibody diluted 1 : 1000, Millipore, MA, USA, Cat \# AB9272; GAPDH diluted 1 : 10000 Millipore, MA, USA, Cat \# MAB374; Pro-granulin antibody diluted 1 : 1000 Invitrogen, MA, USA, Cat \# PA5-46995; 4G8 diluted 1 : 500 Biolegend CA, USA Cat \# SIG-39229; 22C11 (in-house) antibody diluted 1 : 500). Blots were rinsed in TBST and incubated with appropriate secondary antibody at room temperature for 1 h (IRDye800 Goat anti-mouse Cat \# LCR926-32210; IRdye800 Goat anti-Rabbit Cat \# LCR926-32211; IRDye680 Goat anti-mouse Cat \# LCR926-68070; IRDye680 Goat anti-Rabbit Cat \# LCR926-68071; IRDye800 Goat anti-rat Cat \# 92632219, LI-COR Biosciences, Lincoln, Nebraska, USA), followed by further rinsing and imaged using a LI-COR Odyssey Imaging system (LI-COR Biosciences, Lincoln NE, USA), and analyzed with Image Studio Lite software (LI-COR Biosciences, Lincoln NE, USA). Sample data were normalized to total protein loaded and to the GAPDH loading control and then expressed as arbitrary units based upon densitometric quantitation.

LA-ICP-MS imaging {#sec0035}
-----------------

Analysis was performed using a New Wave Research UP213 laser ablation system with a two-volume large format cell (ablation area 15×15 cm). This system was hyphenated to an Agilent Technologies 7500ce ICP-MS fitted with 'cs' lenses for enhanced sensitivity. Quantitative data was obtained by representative ablation of matrix-matched tissue standards produced according to the protocol previously reported \[[@ref034]\]. Hydrogen was used as a reaction gas at a flow rate of 3 mL min^--1^ to remove potential interferences arising from trace oxygen impurities in the argon gas used, particularly ^40^Ar^16^O^+^ on ^56^Fe^+^ \[[@ref035]\]. The specificity of hydrogen for reducing interference on Fe was the main determinant of its selection; non-specific collision gases such as helium reduce signal to noise ratios and do not attenuate interferences effectively in LA-ICP-MS \[[@ref036]\]. We have recently shown that matrix-based interference formation at biologically-relevant concentrations are negligible using these experimental conditions \[[@ref037]\]. Measured masses included *m/z* = 56 for Fe, 62 for Cu, and 66 for Zn with an integration time of 0.08 seconds per mass. Limits of detection (LOD) and quantification (LOQ) were 0.55 μg g^--1^ and 1.58 μg g^--1^ for Fe; 1.20 μg g^--1^ and 1.89 μg g^--1^ for Cu; and 0.39 μg g^--1^ and 1.08 μg g^--1^ for Zn. A representative image ([Fig. 1](#jad-60-jad170322-g001){ref-type="fig"}) reconstruction is provided for Fe, Cu, and Zn.

![Representative LA-ICPMS schematic of SSV (top row) and trehalose (bottom row) treated Tg2576 brain sections showing Fe, Cu, and Zn. Scale bar = 1 mm.](jad-60-jad170322-g001){#jad-60-jad170322-g001}

Image construction and region of interest selection {#sec0040}
---------------------------------------------------

Lines of ablation were spaced apart the same distance as the laser beam diameter. A beam diameter of 30 μm was used, traversing the section at a speed of 120 μm s^--1^, laser fluence of 0.3 J cm^--2^ and repetition rate of 20 Hz. The ICP-MS was configured to collect 4 data points per second \[[@ref035]\] thus the resultant images had pixel dimensions was equivalent to 30×30 μm^2^ (total pixel area = 900 μm^2^). Images were produced by reducing multiple ablation lines into ASCII data files *via* a Python script for importing into ENVI 6.0 (Exelis Visual Information Solutions, Boulder, CO, USA), from which regions of interest (ROIs) were extracted and statistically analyzed. One brain slice hemisphere per animal underwent ablation and subsequent analysis. Additionally, the hippocampus was manually extracted as an individual ROI using the Zn map \[[@ref038]\] for analysis without adjacent cortical tissue, and hippocampal areas CA1, CA2 and CA3 were also subsequently manually extracted.

Statistical analysis {#sec0045}
--------------------

Statistical analysis was carried out in Prism 6.0 h (Graph-Pad, La Jolla, CA, USA). Analysis was carried out using either a two-tailed *t* test or a two-way repeated measures ANOVA as appropriate, with significance recognized as *p* \< 0.05.

RESULTS {#sec0050}
=======

Behavior {#sec0055}
--------

A two-way repeated measure analysis with a *post-hoc* Bonferroni's analysis of the water maze revealed that trehalose treated mice (*n* = 15) demonstrated a significantly (*p* \< 0.0081) enhanced task acquisition (learning) across the trial, as compared to the vehicle control group (*n* = 12) ([Fig. 2a](#jad-60-jad170322-g002){ref-type="fig"}). In addition, trehalose-treated mice performed significantly (*p* \< 0.0003) better in the probe trial ([Fig. 2b](#jad-60-jad170322-g002){ref-type="fig"}), indicating an improvement in memory recall. An absence of any significant difference in swim speed suggests that overall, there is a robust improvement in cognition for the trehalose treated mice. No significant differences were observed between wild-type SSV treated mice and Tg2576 SSV treated mice, most likely as a result of the advanced age of the animals and the anticipated confound of normal age-related cognitive deficits. Further studies in younger mice would help delineate the potential differential effect on disease versus aging-related pathways in relation to cognitive performance. Indeed, it remains possible that trehalose may impact normal aging, as wild-type trehalose treated mice showed a trend toward better performance as compared to wildtype SSV treated and Tg2576 SSV treated mice, although this did not reach statistical significance.

![Trehalose treatment improves cognitive performance of Tg2576 mice in the Morris water maze. Two-way repeated measures ANOVA (++*p* \< 0.0081) revealed a significant decrease in escape latency for Tg2576 trehalose treated mice compared to Tg2576 SSV treated litter mate controls over the course of the trial ([Fig. 1a](#jad-60-jad170322-g001){ref-type="fig"}). A Bonferroni's *post-hoc* analysis further revealed a significant decrease in latency for trehalose treated mice on day six (^\*^*p* = 0.0233). Two-tailed *t*-test revealed a significant (^\*\*\*^*p* \< 0.0003) increase in time spent in the relevant quadrant for trehalose treated Tg2576 mice compared to SSV treated Tg2576 control littermates on probe day ([Fig. 3b](#jad-60-jad170322-g003){ref-type="fig"}).](jad-60-jad170322-g002){#jad-60-jad170322-g002}

Metal analyses {#sec0060}
--------------

Assessment of Fe concentrations via LA-ICPMS revealed no significant difference between trehalose (*n* = 7) and SSV (*n* = 7) treated mice, in the cortex ([Fig. 3a](#jad-60-jad170322-g003){ref-type="fig"}), hippocampus ([Fig. 3b](#jad-60-jad170322-g003){ref-type="fig"}) or in the CA1 ([Fig. 3c](#jad-60-jad170322-g003){ref-type="fig"}), CA2 ([Fig. 3d](#jad-60-jad170322-g003){ref-type="fig"}) or CA3 ([Fig. 3e](#jad-60-jad170322-g003){ref-type="fig"}) regions of the hippocampus.

![Trehalose does not alter metal levels in Tg2576 mice. Fe was unaltered between trehalose and SSV treated animals in all areas assessed ([Fig. 3a-e](#jad-60-jad170322-g003){ref-type="fig"}). Similarly, Zn was unaltered between trehalose and SSV treated animals in all areas assessed ([Fig. 3f-j](#jad-60-jad170322-g003){ref-type="fig"}). Cu also revealed non-significant changes between trehalose and SSV treated animals in all areas assessed ([Fig. 3k-o](#jad-60-jad170322-g003){ref-type="fig"}).](jad-60-jad170322-g003){#jad-60-jad170322-g003}

Similarly, Zn concentrations also revealed no significant difference between trehalose (*n* = 7) and SSV (*n* = 7) treated mice, in the cortex ([Fig. 3f](#jad-60-jad170322-g003){ref-type="fig"}), hippocampus ([Fig. 3g](#jad-60-jad170322-g003){ref-type="fig"}) or in the CA1 ([Fig. 3h](#jad-60-jad170322-g003){ref-type="fig"}), CA2 ([Fig. 3i](#jad-60-jad170322-g003){ref-type="fig"}), or CA3 ([Fig. 3j](#jad-60-jad170322-g003){ref-type="fig"}) regions of the hippocampus. Furthermore, Cu concentrations were also unchanged for trehalose (*n* = 7) and SSV (*n* = 7) treated mice, in the cortex ([Fig. 3k](#jad-60-jad170322-g003){ref-type="fig"}), hippocampus ([Fig. 3l](#jad-60-jad170322-g003){ref-type="fig"}) or in the CA1 ([Fig. 3m](#jad-60-jad170322-g003){ref-type="fig"}), CA2 ([Fig. 3n](#jad-60-jad170322-g003){ref-type="fig"}), or CA3 ([Fig. 3o](#jad-60-jad170322-g003){ref-type="fig"}) regions of the hippocampus. Analysis also confirmed no significant elevation or reduction in Fe, Zn, or Cu between Tg2576 and wild-type mice.

Western blotting {#sec0065}
----------------

Results indicated a significant increase (+48%) in DCX (vehicle, 0.15±0.009, *n* = 8; trehalose 0.24±0.040, *n* = 8; *p* = 0.0401; [Fig. 4a](#jad-60-jad170322-g004){ref-type="fig"}) and synaptophysin (+147%) (vehicle, 0.22±0.122, *n* = 8; trehalose 1.46±0.162, *n* = 8; *p* = 0.0001; [Fig. 4b](#jad-60-jad170322-g004){ref-type="fig"}) protein expression in the hippocampus only of trehalose treated mice. Additionally, a significant increase in progranulin protein expression was observed in the trehalose treated group in both the cortex (+43%) (vehicle, 3.81±0.62, *n* = 8; trehalose 5.95±0.13, *n* = 8; *p* = 0.0052; [Fig. 4c](#jad-60-jad170322-g004){ref-type="fig"}) and hippocampus (+33%) (vehicle, 4.00±0.53, *n* = 8; trehalose, 5.62±0.17, *n* = 8; *p* = 0.0126; [Fig. 4d](#jad-60-jad170322-g004){ref-type="fig"}), when compared with the SSV control group. Soluble and membrane fractions of cortex (Soluble; vehicle, 0.55±0.02, *n* = 8; trehalose, 0.52±0.02, *n* = 8; *p* = 0.3466; [Fig 5a](#jad-60-jad170322-g005){ref-type="fig"}. Membrane; vehicle 1.51±0.16, *n* = 8, trehalose, 1.49±0.10, *n* = 8; *p* = 0.9377; [Fig. 5c](#jad-60-jad170322-g005){ref-type="fig"}) and hippocampus (Soluble; vehicle 0.39±0.04, *n* = 8; trehalose, 0.42±0.01, *n* = 8; *p* = 0.5767; [Fig. 5b](#jad-60-jad170322-g005){ref-type="fig"}. Membrane; vehicle 1.07±0.05, *n* = 8; trehalose, 1.12±0.06, *n* = 8; *p* = 0.5649; [Fig. 5d](#jad-60-jad170322-g005){ref-type="fig"}) were also assessed for AβPP levels; however, no significant differences were observed. Similarly, there were no differences observed in any Aβ fragments following trehalose treatment (data not shown). Autophagy was assessed via LC3 ([Fig. 6](#jad-60-jad170322-g006){ref-type="fig"}); however, there was no significant difference in the ratio between LC3-1 and LC3-2 for trehalose treated animals when compared to controls in either the cortex (vehicle 0.80±0.04, *n* = 8; trehalose, 0.90±0.04, *n* = 8; *p* = 0.15) or the hippocampus (vehicle, 0.46±0.02, *n* = 8; trehalose, 0.39±0.02, *n* = 8; *p* = 0.10).

![Trehalose significantly increases synaptophysin, Doublecortin (DCX) and Progranulin. A significant increase in DCX protein levels was observed in the hippocampus of the trehalose treated mice (^\*^*p* = 0.0401) (a). Similarly, a significant increase in synaptophysin levels was also observed in the hippocampus (^\*\*\*\*^*p* = 0.0001) (b). Progranulin protein expression was also shown to be significantly elevated in both the cortex (^\*\*^*p* = 0.0052) (c) and the hippocampus (^\*^*p* = 0.0126) (d).](jad-60-jad170322-g004){#jad-60-jad170322-g004}

![Trehalose does not alter AβPP expression. Trehalose did not significantly alter the expression of AβPP in the soluble fraction of cortex (a) or hippocampus (b), nor in the membrane fraction of cortex (c) or hippocampus (d).](jad-60-jad170322-g005){#jad-60-jad170322-g005}

![Trehalose does not alter LC3-1. Ratio of LC3-1 to LC3-2 revealed no significant difference between the trehalose treated group when compared to their SSV treated littermates.](jad-60-jad170322-g006){#jad-60-jad170322-g006}

DISCUSSION {#sec0070}
==========

The data presented herein demonstrates that trehalose treatment enhanced the cognitive performance of the Tg2576 mouse model of AD in the Morris water maze. Trehalose treated mice performed significantly better during the learning phase of the trial, and importantly, demonstrated enhanced memory retention on the probe day of the trial when compared to SSV treated littermate controls. Our data concurs with previously published work in which an Amyloid Precursor Protein/Presenilin 1 (APP/PS1) transgenic mouse model of AD was utilized to assess the therapeutic efficacy of intracerebral injections of trehalose \[[@ref001]\]. Importantly, however, this study recapitulates the data in a different transgenic mouse model of AD using the more physiologically and therapeutically relevant route of oral administration. Moreover, this study also identifies biochemical pathways modulated by trehalose that may play a role in cognition, an observation that has not previously been reported in animal studies using a trehalose-treatment paradigm. These findings both support the use of trehalose in the treatment of AD, and also present the potential for trehalose to be utilized in other neurodegenerative disorders.

Due to the key role played by metals in both the pathogenesis of AD and in learning and memory \[[@ref029]\], we initially performed an analysis of the spatial distribution and concentration of Fe, Zn, and Cu in the brains of both trehalose treated and untreated mice. Many other studies have shown metal modulation to have beneficial pathological and physical outcomes \[[@ref027]\], and so this would allow us to assess whether there was any correlation between these metals and the observed behavioral improvement in the trehalose-treated mice. To assess metal concentrations, we utilized LA-ICPMS imaging of brain slices, which has previously been used to effectively discriminate brain metal differences in both human AD \[[@ref041]\] and aged mouse tissue \[[@ref040]\].

The Tg2576 mice have previously been shown to have an age-dependent reduction in brain Cu and Zn levels, with males showing an age-related reduction in Fe while aged females showed an increase in Fe \[[@ref042]\]; observations which were accredited to the overexpression of AβPP and Aβ. Our results indicated no significant change for Fe, Cu, or Zn concentrations, in any region assessed between the trehalose treated and non-treated groups ([Fig. 3a-o](#jad-60-jad170322-g003){ref-type="fig"}). A possible explanation as to the discrepancy between these results could be that the abovementioned study utilized a bulk tissue lysate analysis, whereas our study is regionally defined. Our data also revealed no significant differences in metal concentrations between wild-type and Tg2576 mice, which may reflect the age of the wild-type mice used in this study, as metal accumulation in the aging mouse brain has been previously noted in the literature \[[@ref042]\].

Nevertheless, we found the lack of metal modulation to be perplexing as trehalose has been demonstrated to induce autophagy and reduce pathological metal associated protein aggregates in many cell models \[[@ref043]\] and affect behavioral improvements in mouse models of neurodegenerative disease presumably via the same mechanism \[[@ref004]\]. We therefore assessed autophagy by evaluating LC3-2 protein expression via western blotting, whereby upon autophagic induction, LC3 is converted from a cytosolic form (LC3-1) to a phosphatidylethanolamine-conjugated form (LC3-2), and thereby subsequently recruited to membranes of autophagasomes \[[@ref048]\]. We revealed no significant difference between the LC3-1 to LC3-2 ratio between trehalose treated and non-treated groups ([Fig. 6](#jad-60-jad170322-g006){ref-type="fig"}), indicating that the beneficial behavioral effect we observed with trehalose was unlikely to be due to an autophagy-mediated effect on protein aggregates. Given this, it is possible that the lack of any reduction in metal may be due to the absence of autophagy mediated degradation of protein aggregates that are implicated in the dyshomeostasis of metals observed in AD. Zinc, for example, has been shown to accumulate in the pathological extracellular plaques of AD \[[@ref049]\], and can bind Aβ causing rapid aggregation and precipitation of the Aβ peptide \[[@ref053]\]. Trehalose has been shown to inhibit aggregation and neurotoxicity of Aβ in cell culture \[[@ref046]\], and significantly reduce the number of amyloid deposits in APP/PS1 mice \[[@ref001]\]. Had autophagy been induced and affected a change in Aβ aggregation in this study, it is likely that we would have detected a change in the localized zinc concentrations.

A recent publication by Tien et al. \[[@ref054]\], for example, revealed that trehalose altered the subcellular trafficking and metabolism of AβPP. We therefore assessed the protein expression levels of AβPP due to its contribution to Aβ formation in the Tg2576 mouse and human AD. Our results indicated no significant differences in AβPP protein expression levels in soluble and membrane extracted fractions from the cortex or hippocampus of trehalose treated and non-treated mice using the anti-AβPP antibody 22C11 ([Fig. 5a-d](#jad-60-jad170322-g005){ref-type="fig"}). Further analysis of the membrane fractions with the Aβ antibodies, WO2 and 4G8, also revealed no significant alteration in any Aβ species (data not shown). It should be noted, however, that the results of Tien et al. \[[@ref053]\] coincided with robust LC3-II protein accumulation, indicating enhanced autophagy, which was not observed in this current study.

We therefore hypothesized that trehalose may be indirectly increasing synaptic activity. Accordingly, we assessed the pre-synaptic vesicle protein synaptophysin, which is a surrogate marker for the number of synapses, via western blot and revealed a significant increase in synaptophysin expression in the hippocampus, but not the cortex, of trehalose treated mice ([Fig. 4b](#jad-60-jad170322-g004){ref-type="fig"}). Many murine studies have linked increased synaptophysin expression with enhanced spatial memory \[[@ref055]\]. Moreover, loss of this pre-synaptic protein in the hippocampus correlates with the cognitive decline in AD \[[@ref058]\].

We also probed for doublecortin, the endogenous early neuronal marker and surrogate indicator of neurogenesis \[[@ref059]\], and revealed a significant increase in DCX expression in the hippocampus of the trehalose treated mice ([Fig. 4a](#jad-60-jad170322-g004){ref-type="fig"}) that was not observed in the cortex, nor in the vehicle treated tissue. The hippocampus is the most susceptible brain region in AD, whereby cell death and associated degeneration of the tissue is likely to be the underlying cause of memory deficits \[[@ref060]\]. However, the role of neurogenesis in AD and in the hippocampus of transgenic murine models of AD has previously resulted in controversial and contraindicative results \[[@ref062]\]. Nevertheless, decreased neurogenesis correlating with an increase in Aβ burden has been shown in a transgenic mouse model of AD \[[@ref062]\], and the potential of modulating hippocampal neurogenesis as a therapeutic approach for AD has been proposed \[[@ref066]\].

We also assessed the secreted growth factor Progranulin, a known regulator of neuronal growth and survival \[[@ref067]\]. We hypothesized that trehalose may upregulate progranulin expression as it has been demonstrated to do so in human and mouse models of progranulin haploinsufficiency \[[@ref007]\]. Western blot analysis revealed a significant increase in progranulin in both the hippocampus ([Fig. 4c](#jad-60-jad170322-g004){ref-type="fig"}) and cortex ([Fig. 4d](#jad-60-jad170322-g004){ref-type="fig"}) of trehalose treated mice. Interestingly, progranulin has previously been shown to be protective against Aβ toxicity \[[@ref069]\], and progranulin missense mutations contribute to the risk for clinically diagnosed AD \[[@ref070]\]. The observation that trehalose can elevate progranulin protein expression in an AD transgenic mouse model, therefore, suggests another possible mechanism of action of this compound.

Conclusion {#sec0075}
----------

Our results demonstrate that trehalose administration can improve cognitive outcomes in the Tg2576 transgenic mouse model of AD. Given that trehalose is FDA "GRAS", has a generous safety profile, and is currently used as an excipient in many pharmaceutical formulations for human use, we believe that trehalose could be a viable candidate for further pharmacological investigation as a potential therapeutic option for patients with AD, either as a monotherapy or in conjunction with other treatment alternatives.
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